|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
HPV mRNA E6/E7, Rectal
Test Code91932
CPT Codes
87624
Preferred Specimen
Dacron swab collected in 3 mL Liquid Cytology (PreservCyt®) Preservative (ThinPrep®) vial
Minimum Volume
1.5 mL
Other Acceptable Specimens
Anal-Rectal brush collected in 3 mL of Liquid Cytology Preservative (ThinPrep®) vial
Instructions
To collect an anal-rectal sample, a wetted, non-lubricated Dacron/Polyester swab is used. The Dacron/Polyester swab is inserted about 3 cm (or until resistance is met) into the anal canal past the anal verge, into the rectal vault. This is done without visualization of the anal canal. Firm lateral pressure is applied to the swab handle as it is rotated and slowly moved in and out. Slowly withdraw swab from the anal canal. Swish the swab vigorously in PreservCyt® fluid in the ThinPrep® vial. Discard the swab. Cap and tighten the ThinPrep® vial.
Follow the same procedure if using a brush to collect an anal-rectal sample. Avoid using cotton swab on a wooden stick because the handle may break and splinter during collection. Swab that is grossly contaminated with feces should be discarded and the collection repeated.
Follow the same procedure if using a brush to collect an anal-rectal sample. Avoid using cotton swab on a wooden stick because the handle may break and splinter during collection. Swab that is grossly contaminated with feces should be discarded and the collection repeated.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 30 days
Refrigerated: 28 days
Frozen: Unacceptable
Refrigerated: 28 days
Frozen: Unacceptable
Methodology
Transcription-Mediated Amplification (TMA)
FDA Status
The analytical performance characteristics of this assay have been determined by Quest Diagnostics. The modifications have not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Tues-Sat; Report available: 2-5 days
Reference Range
Not detected
Clinical Significance
The presence of E6/E7 messenger RNA from 14 high risk HPV types indicates incorporation of HPV DNA into the host cells. Proteins expressed from E6-E7 polycistronic mRNA alter cellular p53 and retinoblastoma protein functions, leading to disruption of cell-cycle check points and cell genome instability. This information, together with the physician’s assessment of cytology history, other risk factors, and professional guidelines, may be used to guide patient management.
